Mycophenolate Mofetil Accord

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Accord, is an immunosuppressant (antimetabolite) presented as an oral formulation for systemic use. It is employed to prevent organ transplant rejection and to treat certain autoimmune disorders such as lupus nephritis in adult patients.

GNH USA supplies Mycophenolate Mofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required.

Mycophenolate Mofetil is used in immunosuppressive therapy to reduce immune‑mediated damage in transplant and autoimmune settings.

- Kidney transplant rejection: helps prevent graft rejection by inhibiting lymphocyte proliferation. - Heart transplant rejection: supports long‑term graft survival through immune suppression. - Liver transplant rejection: reduces risk of acute rejection episodes after transplantation. - Lupus nephritis: contributes to disease control by decreasing renal inflammation.

Mycophenolate Mofetil may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Tremor - Elevated liver enzymes

Serious or Rare Side Effects: - Severe infection risk - Bone‑marrow suppression (leukopenia, anemia, thrombocytopenia) - Progressive multifocal leukoencephalopathy (PML) - Pregnancy loss or fetal toxicity

When prescribing Mycophenolate Mofetil, several safety considerations should be observed.

- Pregnancy: contraindicated (Category X); avoid use in pregnant women. - Infection: monitor for signs of opportunistic infections and treat promptly. - Hematology: perform regular complete blood counts to detect bone‑marrow suppression. - Renal function: adjust dosing in patients with impaired renal clearance. - Hepatic function: assess liver enzymes before initiation and periodically. - Store at ambient temperature: keep below 25 °C, in original container, protect from moisture and light.

Mycophenolate Mofetil interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce absorption of mycophenolic acid. - Azathioprine: additive bone‑marrow suppression. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Cyclosporine or tacrolimus: may increase mycophenolate levels; monitor renal function. - Cholestyramine: may decrease drug exposure. - Rifampin: may lower mycophenolate concentrations. - Oral contraceptives: may have reduced efficacy; advise alternative contraception.